

ASTRAZENECA PLC
Form 6-K
April 24, 2014

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of April 2014

Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82- _____

ASTRAZENECA DEVELOPMENT PIPELINE

AS AT 31 MARCH 2014

NMEs

Phase III / Registration

Submission dates shown for assets in Phase III and beyond. As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

| Compound | Mechanism | Area Under Investigation | Date Commenced Phase | Estimated Filing | | | |
|-------------------------------|---|--------------------------------|----------------------|------------------|----------|----------|----------|
| | | | | US | EU | Japan | China |
| Cardiovascular and Metabolism | | | | | | | |
| Brilinta / Brilique1 | ADP receptor antagonist | arterial thrombosis | | Launched | Launched | Filed | Launched |
| Epanova# | omega-3 fatty acids | free hypertriglyceridaemia | | Filed | | | |
| Farxiga / Forxiga2 | SGLT-2 inhibitor | diabetes | | Launched | Launched | Approved | Filed |
| Myalept | leptin analogue | lipodystrophy | | Approved | 2015 | N/A | |
| Oncology | | | | | | | |
| Caprelsa | VEGFR / EGFR tyrosine kinase inhibitor with RET kinase activity | medullary thyroid cancer | | Launched | Launched | Q3 2014 | Filed |
| moxetumomab pasudotox# | anti-CD22 recombinant immunotoxin | hairy cell leukaemia | Q2 2013 | 2018 | 2018 | | |
| olaparib | PARP inhibitor | BRCAM PSR ovarian cancer | | Filed3 | Filed | | |
| olaparib SOLO-1 | PARP inhibitor | 1st line BRCAM ovarian cancer | Q3 2013 | 2017 | 2017 | 2017 | 2017 |
| olaparib SOLO-2 | PARP inhibitor | BRCAM PSR ovarian cancer | Q3 2013 | 2016 | 2016 | 2016 | 2016 |
| olaparib GOLD | PARP inhibitor | 2nd line gastric cancer | Q3 2013 | | | 2017 | 2018 |
| olaparib OlympiAD | PARP inhibitor | metastatic breast cancer | Q2 20144 | 2016 | 2016 | 2017 | |
| selumetinib# (ARRY-142886) | MEK inhibitor | 2nd line KRAS+ NSCLC | Q4 2013 | 2017 | 2017 | | |
| SELECT-1 selumetinib# | MEK inhibitor | differentiated thyroid cancer5 | Q3 2013 | 2017 | 2017 | | |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

(ARRY-142886)

ASTRA

selumetinib# MEK uveal melanoma5 Q1 20146 2015 2015

(ARRY-142886)inhibitor

SUMIT

Phase III / Registration (continued)

| Compound | Mechanism | Area Under Investigation | Date Commenced Phase | Estimated Filing | | | |
|--|--|---|----------------------|------------------|----------|-------|---------|
| | | | | US | EU | Japan | China |
| Respiratory, Inflammation and Autoimmunity | | | | | | | |
| benralizumab# | anti-IL-5R MAb | severe asthma | Q4 2013 | 2016 | 2016 | | |
| brodalumab# | anti-IL-17R MAb | psoriasis | Q3 2012 | ++ | ++ | | |
| AMAGINE-1,2,3 | | | | | | | |
| brodalumab# | anti-IL-17R MAb | psoriatic arthritis | Q1 2014 | ++ | ++ | | |
| AMVISION-1,2 | | | | | | | |
| lesinurad | selective uric acid reabsorption inhibitor (SURI) | chronic treatment of patients with gout | Q4 2011 | Q4 2014 | Q4 2014 | | 2017 |
| PT003 GFF | LAMA / LABA | COPD | Q2 2013 | 2015 | 2016 | | |
| PT001 GP | LAMA | COPD | Q2 2013 | 2015 | 2016 | | |
| Infection | | | | | | | |
| CAZ AVI# (CAZ104) | cephalosporin / beta lactamase inhibitor | serious infections | Q1 2012 | N/A | Q4 2014 | 2015 | 2016 |
| RECLAIM | | | | | | | |
| CAZ AVI# (CAZ104) | cephalosporin / beta lactamase inhibitor | hospital-acquired pneumonia / ventilator-associated pneumonia | Q2 2013 | N/A | 2017 | 2017 | 2018 |
| REPROVE | | | | | | | |
| Zinforo# | extended spectrum cephalosporin with affinity to penicillin-binding proteins | pneumonia / skin infections | | N/A | Launched | N/A | Q2 2014 |
| Neuroscience | | | | | | | |
| naloxegol# (NKTR-118) | oral peripherally-acting mu-opioid receptor antagonist | opioid-induced constipation | | Filed | Filed | | |

Partnered product.

++ Filing is the responsibility of the partner.

1 Brilinta in the US; Brilique in rest of world.

2 Farxiga in the US; Forxiga in rest of world.

3 FDA accepted submission April 2014.

4 First patient randomised April 2014.

5 These indications previously included under the broad Phase II project listing.

6 First patient expected to dose early Q2 2014.

NMEs

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Phases I and II

| Compound | Mechanism | Area Under Investigation | Phase | Date Commenced Phase | Estimated Filing | | | |
|-------------------------------|--|--|-------|----------------------|------------------|----|-------|-------|
| | | | | | US | EU | Japan | China |
| Cardiovascular and Metabolism | | | | | | | | |
| AZD1722# | NHE3 inhibitor | ESRD-Pi CKD with T2DM / ESRD-fluid retention | II | Q1 2013 | | | | |
| AZD4901 | hormone modulator | polycystic ovarian syndrome | II | Q2 2013 | | | | |
| roxadustat# (FG-4592) | hypoxia-inducible factor inhibitor | anaemia in CKD / ESRD | III | | 2018 | NA | NA | 2016 |
| MEDI6012 | LCAT | arterial thrombosis | I | Q1 2012 | | | | |
| MEDI8111 | Rh-factor II | trauma / bleeding | I | Q1 2014 | | | | |
| Oncology | | | | | | | | |
| AZD1775# | WEE-1 inhibitor | ovarian cancer | II | Q4 2012 | | | | |
| AZD2014 | mTOR serine / threonine kinase inhibitor | solid tumours | II | Q1 2013 | | | | |
| AZD4547 | FGFR tyrosine kinase inhibitor | solid tumours | II | Q4 2011 | | | | |
| MEDI-551# | anti-CD19 MAb | haematological malignancies | II | Q1 2012 | | | | |
| MEDI-573# | anti-IGF MAb | metastatic breast cancer | II | Q2 2012 | | | | |
| MEDI4736# | anti-PD-L1 MAb | NSCLC | II | Q1 2014 | | | | |
| selumetinib# (ARRY-142886) | MEK inhibitor | 2nd line KRAS-NSCLC | II | Q1 2013 | | | | |
| tremelimumab | anti-CTLA4 MAb | mesothelioma | II | Q2 2013 | | | | |
| AZD5363# | AKT kinase inhibitor | breast cancer | II | Q1 2014 | | | | |
| AZD1208 | PIM kinase inhibitor | haematological malignancies | I | Q1 2012 | | | | |
| AZD6738 | ATR serine / threonine kinase inhibitor | CLL / head & neck | I | Q4 2013 | | | | |
| AZD8186 | PI3 kinase beta inhibitor | solid tumours | I | Q2 2013 | | | | |
| AZD9150# | STAT3 inhibitor | haematological malignancies | I | Q1 2012 | | | | |
| AZD9291 | EGFR tyrosine kinase inhibitor | solid tumours | I | Q1 2013 | | | | |
| MEDI-565# | | solid tumours | I | Q1 2011 | | | | |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | | | | |
|--|---|---------------|---|---------|--|
| | anti-CEA BiTE MAb | | | | |
| MEDI0639# | anti-DLL-4 MAb | solid tumours | I | Q2 2012 | |
| MEDI0680 (AMP-514) | anti-PD-1 MAb | solid tumours | I | Q4 2013 | |
| MEDI3617# | anti-ANG-2 MAb | solid tumours | I | Q4 2010 | |
| MEDI4736# + tremelimumab | anti-PD-L1 MAb + anti-CTLA4 MAb | solid tumors | I | Q4 2013 | |
| MEDI4736# + dabrafenib + trametinib2 | anti-PD-L1 MAb + BRAF inhibitor + MEK inhibitor | melanoma | I | Q1 2014 | |
| MEDI6469# | murine anti-OX40 MAb | solid tumours | I | Q1 2006 | |

NMEs

Phases I and II (continued)

| Compound | Mechanism | Area Under Investigation | Phase | Date Commenced Phase | Estimated Filing | | | |
|--|---|--|-------|----------------------|------------------|----|-------|-------|
| | | | | | US | EU | Japan | China |
| Oncology (continued) | | | | | | | | |
| moxetumomab pasudotox# | anti-CD22 recombinant immunotoxin | pALL | I | Q3 2008 | | | | |
| volitinib# (AZD6094) | MET tyrosine kinase inhibitor | solid tumours | I | Q1 2012 | | | | |
| Respiratory, Inflammation and Autoimmunity | | | | | | | | |
| AZD2115# | MABA | COPD | II | Q2 2012 | | | | |
| AZD5069 | CXCR2 antagonist | asthma | II | Q4 2010 | | | | |
| anifrolumab# (MEDI-546) | anti-IFN-alpha MAb | RSLE | II | Q1 2012 | | | | |
| benralizumab# | anti-IL-5R MAb | COPD | II | Q4 2010 | | | | |
| brodalumab# | anti-IL-17R MAb | asthma | II | Q2 2013 | | | | |
| mavrilimumab# | anti-GM-CSFR MAb | rheumatoid arthritis | II | Q1 2010 | | | | |
| MEDI2070# | anti-IL-23 MAb | Crohn's disease | II | Q1 2013 | | | | |
| MEDI7183# | anti-a4b7 MAb | Crohn's disease / ulcerative colitis | II | Q4 2012 | | | | |
| MEDI8968# | anti-IL-1R MAb | COPD / HS | II | Q4 2011 | | | | |
| RDEA3170 | selective uric acid reabsorption inhibitor | chronic management of hyperuricaemia in patients with | II | Q3 2013 | | | | |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | | | |
|----------------------------|--|---|---------|--------------------|
| sifalimumab# (MEDI-545) | (SURI) anti-IFN-alpha Mab | gout SLE | II | Q3 2008 |
| tralokinumab AZD1419 | anti-IL-13 MAb TLR9 | asthma / IPF asthma | II I | Q1 2008 Q3 2013 |
| AZD4721 | antagonist CXCR2 | COPD | I | Q3 2013 |
| AZD7624 | antagonist inhaled P38 inhibitor | COPD | I | Q1 2013 |
| AZD8848# | inhaled TLR7 antagonist | asthma | I | Q2 2012 |
| MEDI-551# | anti-CD19 MAb | multiple sclerosis | I | Q3 2012 |
| MEDI5872# | anti-B7RP1 Mab | SLE | I | Q4 2008 |
| MEDI9929# PT010 | anti-TSLP MAb LAMA / LABA / ICS | asthma COPD | I I | Q4 2008 Q4 2013 |
| Infection AZD5847 | oxazolidinone anti-bacterial inhibitor | tuberculosis | II | Q4 2012 |
| CXL# | beta lactamase inhibitor / cephalosporin | MRSA | II | Q4 2010 |
| ATM AVI | monobactam / beta lactamase inhibitor | targeted serious bacterial infections | I | Q4 2012 |
| AZD0914 | GyrAR | serious bacterial infections | I | Q4 2013 |
| MEDI-550 | pandemic influenza virus vaccine | pandemic influenza prophylaxis | I | Q2 2006 |

NMEs

Phases I and II (continued)

| Compound | Mechanism | Area Under Investigation | Phase | Date Commenced Phase | Estimated Filing | | | |
|-----------------------|-----------------------------------|--|-------|----------------------------|------------------|----|-------|-------|
| | | | | | US | EU | Japan | China |
| Infection (continued) | | | | | | | | |
| MEDI-559 (PRVV) | paediatric RSV vaccine | RSV prophylaxis | I | Q4 2008 | | | | |
| MEDI4893 | MAB binding to S. aureus toxin | hospital-acquired pneumonia / serious S. aureus infection | I | Q1 2013 | | | | |
| MEDI92873 | H7N9 vaccine | avian influenza | I | Q4 2013 | | | | |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Neuroscience

| | | | | |
|----------|---------------------------------|--|----|---------|
| AZD3241 | myeloperoxidase inhibitor | Parkinson's disease | II | Q2 2012 |
| AZD5213 | histamine-3 receptor antagonist | Tourette's syndrome / neuropathic pain | II | Q4 2013 |
| AZD3293# | beta-secretase inhibitor | Alzheimer's disease | I | Q4 2012 |
| AZD6423 | NMDA antagonist | suicidal ideation | I | Q3 2013 |

Partnered product.

1 In-licensed asset in late-development but the Phase III AstraZeneca programme has yet to randomise its first patient.

2 MedImmune-sponsored study in collaboration with GSK.

3 Vaccine in development through a CRADA with NIH.

Line Extensions

| Compound | Mechanism | Area Under Investigation | Date Commenced Phase | Estimated Filing | | | |
|--------------------------------------|-------------------------|---|----------------------|------------------|-------|---------|-------|
| | | | | US | EU | Japan | China |
| Cardiovascular and Metabolism | | | | | | | |
| Brilinta / Brilique1 EUCLID | ADP receptor antagonist | outcomes study in patients with peripheral artery disease | Q4 2012 | 2016 | 2016 | 2016 | 2017 |
| Brilinta / Brilique1 PEGASUS-TIMI 54 | ADP receptor antagonist | outcomes study in patients with prior myocardial infarction | Q4 2010 | 2015 | 2015 | 2015 | 2017 |
| Brilinta / Brilique1 SOCRATES | ADP receptor antagonist | outcomes study in patients with stroke or TIA | Q1 2014 | 2016 | 2016 | 2016 | 2017 |
| Brilinta / Brilique1 THEMIS | ADP receptor antagonist | outcomes study in patients with Type 2 diabetes and CAD, but without a previous history of MI or stroke | Q1 2014 | 2017 | 2017 | 2018 | 2018 |
| Bydureon Dual Chamber Pen | GLP-1 receptor agonist | diabetes | | Approved | Filed | Q2 2014 | |
| | | | Q2 2010 | 2018 | 2018 | 2018 | |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | | | | | | |
|--|--|---|---------|----------|-----------|---------|----------|
| Bydureon EXSCEL | GLP-1 receptor agonist | outcomes study | | | | | |
| Bydureon weekly suspension | GLP-1 receptor agonist | diabetes | Q1 2013 | 2015 | 2015 | | |
| Farxiga / Forxiga2 DECLARE- TIMI 58 | SGLT-2 inhibitor | outcomes study | Q2 2013 | 2020 | 2020 | | |
| Kombiglyze XR FDC / Komboglyze FDC3 | DPP-4 inhibitor / metformin FDC | diabetes | | Launched | Launched | | Filed |
| Onglyza SAVOR-TIMI 53 | DPP-4 inhibitor | outcomes study | Q2 2010 | Q1 20144 | Filed | | 2015 |
| saxagliptin / dapagliflozin FDC | DPP-4 inhibitor / SGLT-2 inhibitor FDC | diabetes | Q2 2012 | 2015 | 2015 | | |
| Xigduo XR FDC / Xigduo FDC5 | SGLT-2 inhibitor / metformin FDC | diabetes | | Filed | Approved6 | | |
| Oncology Caprelsa | VEGFR / EGFR tyrosine kinase inhibitor with RET kinase activity | differentiated thyroid cancer | Q2 2013 | 2016 | 2016 | 2016 | |
| Faslodex FALCON | oestrogen receptor antagonist | 1st line advanced breast cancer | Q4 2012 | 2016 | 2016 | 2016 | 2016 |
| Iressa | EGFR tyrosine kinase inhibitor | treatment beyond progression | Q1 2012 | | 2015 | 2015 | 2015 |
| Respiratory, Symbicort7 | Inflammation and Autoimmunity ICS / LABA | Breath Actuated Inhaler asthma / COPD | | | | | |
| Neuroscience Diprivan# | sedative and anaesthetic | conscious sedation | | N/A | Launched | Q4 2014 | Launched |
| Gastrointestinal Entocort | glucocorticoid steroid | Crohn's disease / ulcerative | | Launched | Launched | 2015 | N/A |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | | | | | |
|--------------|-------------------------------|--|----------|----------|-----|----------|
| linaclotide# | GC-C receptor peptide agonist | colitis irritable bowel syndrome with constipation (IBS-C) | N/A | N/A | N/A | 2015 |
| Nexium | proton pump inhibitor | peptic ulcer bleeding | Approved | Launched | N/A | Launched |

Partnered product.

- 1 Brilinta in the US; Brilique in rest of world.
- 2 Farxiga in the US; Forxiga in rest of world.
- 3 Kombiglyze XR in the US; Komboglyze FDC in the EU.
- 4 Filed and awaiting regulatory acceptance.
- 5 Xigduo XR FDC in the US; Xigduo FDC in the EU.
- 6 Approval granted in January 2014 but reported as a progression for FY2013.
- 7 Development of a new BAI device is ongoing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 24 April 2014

By: /s/ Adrian Kemp
 Name: Adrian Kemp
 Title: Company Secretary